CatalYm Announces Initial Data from Ongoing Phase 2a Trial Evaluating GDF-15-targeting Antibody Visugromab in Combination with Nivolumab at ASCO 2023

Oral presentation highlights first data from the GDFATHER-2a trial demonstrating lasting and confirmed responses (as per RECIST criteria) following treatment with visugromab and the anti-PD-1 inhibitor

Related Keywords

Zeiten ,Mecklenburg Vorpommern ,Germany ,Chicago ,Illinois ,United States ,American ,Phil Lhuilier ,Ignacio Melero Bermejo ,Phil Lhuillier ,Stefan Klotter ,Catalym Gmb ,International Coordinating Investigator Prof ,American Society Of Clinical Oncology ,Trophic Communications ,Ted Human Effector Cell Relocation Phase ,American Society ,Clinical Oncology ,Annual Meeting ,Growth Differentiation ,Eugen Leo ,Chief Medical Officer ,International Coordinating Investigator ,Universidad De Navarra ,Phill Huillier ,Chief Executive Officer ,Phill Huilier ,Stephanie May ,Stabile Ertr ,Chart Profi Stefan Klotter ,Blue Chips ,Catalym ,Nnounces ,Nitial ,Data ,Rom ,Ngoing ,Hase ,Trial ,Valuating ,Targeting ,Ntibody ,Isugromab ,Combination ,Nivolumab ,Disco ,023 ,